ASX Stocks Performance: CSL Climbs After Clinical Trial Update Boosts Healthcare Stocks

CSL shares surged nearly 7% on the ASX on Wednesday, July 29, 2026, leading a broad healthcare rally. The biotechnology giant climbed to around A$123.68 after unveiling plans for new clinical trials tied to its Horizon 2 manufacturing process. Healthcare stocks on the ASX jumped nearly 4% at midday, outpacing every other sector. The S&P/ASX 200 rose 0.92%, buoyed further by falling oil prices and strong earnings from Rio Tinto.

Why CSL Shares Jumped Nearly 7% on the ASX

CSL’s (NYSE: CSL) rally stems directly from its announcement of new clinical trial work on immunoglobulin production. The trials aim to confirm efficacy and safety using CSL’s next-generation Horizon 2 process.

• Horizon 2 is designed to significantly boost immunoglobulin yield from the same plasma volume.
• CSL held discussions with both the FDA and the European Medicines Agency beforehand.
• Clinical activities are set to begin in mid-2027 at CSL’s Broadmeadows facility in Australia.

This regulatory pathway update gives CSL a clearer route toward finalizing Horizon 2 approval, a key efficiency driver for its plasma business.

Healthcare Sector Leads a Broader ASX Rally

CSL’s surge helped pull the entire healthcare sector higher on the ASX on Wednesday. The sector’s near-4% gain made it the day’s standout performer by a wide margin.

• Financial stocks also advanced roughly 1% during the same session.
• Commonwealth Bank (ASX: CBA) shares edged up 2.07% alongside the broader rally.
• The S&P/ASX 200 index gained 0.92%, supported by easing oil prices tied to US-Iran ceasefire hopes.

Rio Tinto also posted higher H1 underlying earnings and revenue Wednesday, adding further support to the mining-heavy Australian index.

CSL’s Longer Recovery Story Puts Wednesday’s Gain in Context

Wednesday’s jump extends a rebound that began in early June 2026, when CSL touched a 15-year low. The stock has now climbed roughly 30% off that low point.

• CSL closed Tuesday at A$119.52, up around 3% on the day before Wednesday’s bigger move.
• Despite the rebound, CSL remains down approximately 30% year-to-date.
• Shares still trade about 56% below where they stood 12 months earlier.

Morgan Stanley reaffirmed its positive rating on CSL as of July 22, setting a price target of A$163 per share.

What’s Driving CSL’s Underlying Business Fundamentals

Beyond Wednesday’s trial news, CSL’s core financial guidance remains a key focus for ASX investors. The company projects roughly US$15.2 billion in FY26 revenue at constant currency.

CLS topped estimates as revenue rose to $4.7 billion from a $4.39 billion consensus and EPS reached $2.54 versus $2.31. Guidance also came in ahead of forecasts, with revenue seen at $5.25-$5.55 billion and EPS at $2.88-$3.08.

— TU_Crypto_News (@TU_Crypto_News) July 27, 2026

• CSL expects NPATA of about US$3.1 billion for the same fiscal year.
• Its HEMGENIX gene therapy supplied 22 patients across commercial and trial settings recently.
• Full-year results, including an updated impairment estimate, are due August 18, 2026.

CSL previously deferred its planned Seqirus demerger in October 2025, citing volatility in the US vaccine market, with no new timetable confirmed as of mid-July.

The Recovery Story

CSL’s near-7% jump reflects real regulatory progress, not just sentiment-driven trading. Confirming a clear FDA and EMA pathway for Horizon 2 removes a key uncertainty that had weighed on the stock through its 15-year-low period in June. Morgan Stanley’s A$163 target implies brokerages still see meaningful upside from current levels near A$123.68. With August 18 results approaching, investors will likely watch whether CSL’s operational momentum, not just clinical trial headlines, can sustain this rebound through the rest of 2026.

Disclaimer:

The content shared by Meyka AI PTY LTD is for research and informational purposes only. Meyka is not a financial advisory service, and the information provided should not be treated as investment or trading advice.